Healios CFO to Present at Chardan’s 9th Annual Genetic Medicines Conference

Posted on by

NEW YORK, Oct. 20, 2025 — HEALIOS K.K. (“Healios”) announces that Chief Financial Officer Richard Kincaid will be presenting at Chardan’s 9th Annual Genetic Medicines Conference in New York City on Tuesday, October 21, 2025, at 2:00pm Eastern Time (US). The webcast details are to follow.

Those interested in scheduling a one-on-one meeting with Healios should contact their Chardan representative.

The live and archived webcast will be available on Chardan’s website, with a replay accessible for 60 days.

About Healios:

HEALIOS K.K. is a leading Japanese clinical-stage biotechnology company focused on regenerative medicine using stem cells. The company aims to develop new therapies for diseases lacking effective treatment options. Healios is a pioneer in regenerative medicine development in Japan and holds proprietary global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing MultiStem® (HLCM051), a proprietary cell product consisting of multipotent adult progenitor cells (“MAPCs”) derived from healthy adult donor bone marrow. MultiStem has demonstrated significant anti-inflammatory and immunomodulatory properties applicable to various diseases. It has been tested in late-stage clinical trials involving hundreds of patients, is consistently manufactured at scale in 3D bioreactors, and has shown both safety and potential efficacy in multiple indications. Healios aims to globally advance MultiStem for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next-generation NK cell treatment for solid tumors, enhanced through gene-editing. These cells have exhibited strong anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process, and are currently being prepared for initial human testing in collaboration with Akatsuki Therapeutics. The company has also established a proprietary, gene-edited “universal donor” induced pluripotent stem cell line to develop next-generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas with significant unmet medical needs. Healios was founded in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
  (TSE Growth Code: 4593)
   

Contact:

U.S. Investor Relations:
Lisa M. Wilson
T: 212-452-2793
E:

Richard Kincaid
Executive Officer and Chief Financial Officer
E-mail: ir@healios.jp

“`